CVRx Inc. (CVRX) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 31.9 (OVERSOLD (<32))
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While CVRX currently carries a cautious 43/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.26) and Max Pain ($1.50) forces dealer call-delta covering toward $11.87.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
CVRx Inc. (CVRX) advanced +1.79% to $1.43, trading at 2% of its 52-week range ($1.25 – $11.3). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
MINNEAPOLIS, Oct. 22, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions f
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +10.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CVRX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CVRX. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, CVRx Inc. (CVRX) ranks #556 by composite RQD confidence (43/100, grade D-) and #782 by equity capitalization ($38.0M). Within this direct 5-issuer industry benchmark cohort, NEPH leads on earnings valuation at 29.8x trailing P/E, while NEPH leads on capital efficiency and profitability with 18.9% ROIC and 61.9% gross margin. NEPH currently holds the highest overall quantitative score in the immediate peer group at 73/100 (B) compared with CVRX at 43/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CVRX
ACTIVE
CVRx Inc. | D- | 43/100 | — | 85.3% | -35.0% | +1.79% | $38.0M | Benchmark Subject |
| NEPH Nephros Inc. | B | 73/100 | 29.8x | 61.9% | 18.9% | +3.16% | $35.5M | /neph-vs-cvrx → |
| XTNT Xtant Medical Holdings Inc. | C+ | 69/100 | — | 62.9% | 12.8% | +1.54% | $40.7M | /xtnt-vs-cvrx → |
| TELA TELA Bio Inc. | D- | 36/100 | — | 67.7% | -35.0% | -5.74% | $41.5M | /tela-vs-cvrx → |
| DRIO DarioHealth Corp. | D- | 36/100 | — | 56.6% | -35.0% | -2.93% | $32.4M | /drio-vs-cvrx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), CVRx Inc. (CVRX) reported GAAP revenue of $56.7M (+10.4% vs. FY2024 revenue of $51.3M , and +44.2% cumulative change since FY2023) , GAAP net income of -$53.3M, operating cash flow of -$40.2M, and free cash flow of -$40.8M (-0.6% YoY). On the balance sheet, CVRX closed FY2025 with $104.8M in total assets against $49.5M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $56.7M | -$53.3M | -$40.2M | -$40.8M | $104.8M | $49.5M |
| FY2024 (FY) | 2024-12-31 | $51.3M | -$60.0M | -$39.1M | -$40.5M | $133.4M | $49.3M |
| FY2023 (FY) | 2023-12-31 | $39.3M | -$41.2M | -$39.0M | -$39.0M | — | — |
As of 2026-11-01, CVRx Inc. (NASDAQ: CVRX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $1.43 (+1.79% 1D, market cap $38.0M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, CVRX ranks #556 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), CVRX carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of 85.3%, and ROIC of -35.0%. By comparison, NEPH (Nephros Inc.) holds a B grade (73/100 RQD, P/E 29.8x, ROIC 18.9%, cap $35.5M) and XTNT (Xtant Medical Holdings Inc.) posts a C+ grade (69/100 RQD, P/E N/A, ROIC 12.8%, cap $40.7M). Among the 5-stock peer group, NEPH leads on earnings multiple (29.8x) while NEPH leads on capital efficiency (18.9% ROIC).
Per CVRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001235912), CVRx Inc. generated $56.7M in revenue (+10.4% YoY), -$53.3M in net income, and -$40.8M in free cash flow against $104.8M in total assets and $49.5M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
CVRX last traded at $1.43 (+1.79% on volume of 257,051 shares), positioning the stock -36.73% below its 50-day simple moving average ($2.26) and -72.92% below its 200-day simple moving average ($5.28). Across its 52-week range of $1.25 to $11.30, CVRX sits at the 1.8% percentile with a 14-day RSI of 31.9 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.25 to $1.61).
Why CVRX Stock advanced +1.79% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.